Based on the current week's news, the sentiment is overall positive for Sun Pharma. Here's a summary of the notable events:

* Sun Pharma is focusing on specialty and scaling up its business in India, which is seen as a growth driver.
* Kiran Jani of Jainam Broking has a positive view on Sun Pharma, which suggests that the stock may see an upward trend.
* The company has received regulatory approval in Australia for its acne treatment cream, which is a positive development.

The news tone is positive for Sun Pharma, with three out of four news articles having a positive impact on the stock price. The only neutral article is the one analyzing the factors influencing Sun Pharma's share price, which does not have a clear positive or negative tone.

Notable events from the historical data that are relevant to the current week's news include:

* Sun Pharma's acquisition of three brands from Aksigen Hospital Care to boost its anti-inflammatory portfolio, which had a negative impact on the stock price.
* The company's win of U.S. FDA approval for an anti-fungal injection, which had a positive impact on the stock price.
* Sun Pharma's regulatory approvals and launches of its acne treatment cream in various markets, which have had both positive and negative impacts on the stock price.

Overall, the current week's news suggests that Sun Pharma is making progress in its specialty business and is receiving regulatory approvals for its products, which is likely to have a positive impact on the stock price.